SCHEMBL10043836

SCHEMBL10043836

Cc1cc2c(cn1)cc(-c1cc(NC(=O)NCc3ccc(F)cc3)ccc1C)c(=O)n2C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPK1 P28482 5/20 0.44
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PRMT3 O60678 1/20 0.41
RAB9A P51151 3/20 0.41
POLB P06746 2/20 0.41
KRAS P01116 1/20 0.41
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 2/20 0.40
MAOB P27338 1/20 0.40
HTT P42858 1/20 0.40
EPHX2 P34913 1/20 0.40
CYP3A4 P08684 1/20 0.40
PABPC1 P11940 1/20 0.40
S100A4 P26447 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL501986 0.94 NPC1 (0.47) MAPTMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL10043842 0.91 RAB9A (0.48) MAPTMEN1KMT2AMAPK1ALDH1A1
SCHEMBL10043826 0.91 MAPK1 (0.45) MEN1KMT2AMAPK1SMN1; SMN2RAB9A
SCHEMBL10043840 0.90 MEN1 (0.55) MAPTMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL10043843 0.88 MEN1 (0.53) MAPTMEN1KMT2AMAPK1ALDH1A1
SCHEMBL10043841 0.86 KMT2A (0.46) MEN1KMT2AMAPK1RAB9AKRAS
SCHEMBL10043869 0.85 GAA (0.45) MAPTRAB9APOLBRAF1GAA
SCHEMBL10043828 0.83 RAB9A (0.48) MAPTSMN1; SMN2RAB9APOLBKRAS
SCHEMBL10043745 0.82 SYK (0.45) MAPTALDH1A1SMN1; SMN2RAB9APOLB
SCHEMBL10043855 0.81 SYK (0.43) MAPK1RAB9APOLBRAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MAPT 2514/4885MEN1 4240/4885KMT2A 1257/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MAPT 2514/4885MEN1 4240/4885KMT2A 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.